Sinclair et al. BMC Endocrine Disorders 2014, 14:37 http://www.biomedcentral.com/1472-6823/14/37

RESEARCH ARTICLE

Open Access

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies Alan Sinclair1*, Bruce Bode2, Stewart Harris3, Ujjwala Vijapurkar4, Cristiana Mayer5, Albert Fung4, Wayne Shaw4, Keith Usiskin4, Mehul Desai4 and Gary Meininger4

Abstract Background: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in patients with T2DM